Semaglutide injections effectively support weight loss by regulating appetite and glucose levels, offering benefits for ...

Novo Nordisk NVO shares have lost 5% in the past three months, which translates to approximately $29 billion in market value, ...

For weight loss, weight management, and overall wellness, focus on eating healthy foods, like high-protein meals, legumes, ...

Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.

Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

Three doctors have expressed concerns to Newsweek about weight loss drugs for children, with research suggesting an initial reluctance to prescribe them.

The company noted that Wegovy is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise ...

Whether positive or negative, your mood may feel different on GLP-1 medications. Researchers share why that might be and how ...

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

A new study finds that weight loss drugs Like Ozempic could trigger bone loss. Doctors explain why, and how to protect ...

Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...